Startseite
News
Tech
Finanzbranche
Leadership
Well
Recommends
Fortune 500
Home Page
Already have an account?
SIGN IN
SEARCH
Subscribe Now
Sections
FORTUNE 500
News
Europa
Asia
Tech
AI
Finanzbranche
Personal Finance
Immobilien
Crypto
Leadership
Success
Well
Leben
Health
Mind
Family
Aging Well
Recommends
Credit Cards
Banking
Best High-Yield Savings Accounts
Best Savings Accounts
Best CD Rates
Best Money Market Accounts
Savings Calculator
Insurance
Mortgages
Investing
Loans
Health
Bildung
Top Business Schools
Top Information Technology and Data Schools
Top Health Schools
Business Solutions
Video
Rankings
FORTUNE 500
GLOBAL 500
MOST POWERFUL WOMEN
GREAT PLACE TO WORK LISTS
BEST MBA PROGRAMS
MORE RANKINGS
Analytics
Newsletters
Magazine
December 2023/January 2024
October/November 2023
August/September 2023
June/July 2023
April/May 2023
February/March 2023
Live Media
CEO Initiative
Madison Muller
Health
Lilly wins FDA approval for new drug to slow Alzheimer’s
BY
Madison Muller
,
Robert Langreth
, and others
Health
Hims will follow its Viagra playbook and offer weight-loss drugs that are 85% cheaper than Wegovy—with Mounjaro and Zepbound in its sights next
BY
Madison Muller
,
Jessica Nix
, and others
Health
Demand for weight-loss drug Zepbound is so strong that Eli Lilly is warning patients may leave pharmacies empty-handed
BY
Ike Swetlitz
,
Madison Muller
, and others
Politics
‘Outrageous’: Bernie Sanders has Ozempic demands after study says it costs just $5 per month to manufacture
BY
Madison Muller
,
Robert Langreth
, and others
Health
Ozempic maker Novo Nordisk facing pressure as study finds $1,000 appetite suppressant can be made for just $5
BY
Madison Muller
,
Robert Langreth
, and others
Einzelhandel
Meet the surprise winner of the Ozempic craze: a fast-casual chain selling $18 salads
BY
Madison Muller
and
Bloomberg
Health
Experimental once-a-month weight loss injectable shows lasting results in early study
BY
Madison Muller
and
Bloomberg
Health
Weight-loss injectables like Zepbound are making as big of a splash as Viagra, if not bigger. What you need to know about the ‘miracle drugs’
BY
Emma Court
,
Madison Muller
, and others
Health
North Carolina drops coverage for Wegovy and Ozempic, with implications for anti-obesity drug market projected to hit $100B by 2030
BY
Simone Foxman
,
Madison Muller
, and others
Health
Pfizer rocked by failure of weight-loss pill set to compete with lucrative rivals Ozempic and Mounjaro
BY
Madison Muller
and
Bloomberg
Health
A ‘game-changing’ study backs Wegovy use to cut heart attacks and strokes: ‘This is not just about weight and appearance’
BY
Madison Muller
,
Naomi Kresge
, and others
Health
FDA approves yet another weight loss drug to compete against blockbuster sellers Ozempic and Wegovy
BY
Madison Muller
and
Bloomberg
Health
Weight-loss drugs like Ozempic and Wegovy come with potentially serious side effects, study finds
BY
Madison Muller
and
Bloomberg
Health
Weight-loss drugs like Ozempic and Wegovy may be risky for older people because they melt away all-important muscles, experts say
BY
Madison Muller
and
Bloomberg
Health
Some weight loss pills used as alternatives to Ozempic and Wegovy contain toxic ingredients that are ‘potentially life-threatening’
BY
Madison Muller
and
Bloomberg
Load More